Molecular signatures for vaccine development

Vaccine

Volumn 33, Issue 40, 2015, Pages 5256-5261

  Maertzdorf, J ^a   Kaufmann, S H E ^a   Weiner, J ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Defense response; Signatures; Vaccination

Indexed keywords

BCG VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; PATTERN RECOGNITION RECEPTOR; PNEUMOCOCCUS VACCINE; TOLL LIKE RECEPTOR; TULAREMIA VACCINE; VACCINE; VIRUS VECTOR; YELLOW FEVER VACCINE; INTERFERON; TRANSCRIPTOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ARTICLE; BCG VACCINATION; CELL DIFFERENTIATION; DRUG DESIGN; DRUG FORMULATION; GENE CONTROL; GENE EXPRESSION PROFILING; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFLUENZA; INNATE IMMUNITY; MALARIA; MOLECULAR MEDICINE; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; TULAREMIA; UPREGULATION; VACCINATION; VIRUS IMMUNITY; YELLOW FEVER; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; MEDICAL RESEARCH; PROCEDURES;

ADAPTIVE IMMUNITY; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; INTERFERONS; TRANSCRIPTOME; VACCINES;

EID: 84941811265     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.075     Document Type: Article

References (54)

1. Flanagan K.L., Noho-Konteh F., Ghazal P., Dickinson P. Transcriptional profiling technology for studying vaccine responses: an untapped goldmine. Methods 2013, 60(3):269-274.
2. Wang I.M., Bett A.J., Cristescu R., Loboda A., ter Meulen J. Transcriptional profiling of vaccine-induced immune responses in humans and non-human primates. Microb Biotechnol 2012, 5(2):177-187.
3. Jenner R.G., Young R.A. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 2005, 3(4):281-294.
4. Banchereau R., Baldwin N., Cepika A.M., et al. Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines. Nat Commun 2014, 5:5283.
5. WHO Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 2015, 87(47):461-476.
6. Gomez Lorenzo M.M., Fenton M.J. Immunobiology of influenza vaccines. Chest 2013, 143(2):502-510.
7. Zhu W., Higgs B.W., Morehouse C., et al. A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine 2010, 28(16):2865-2876.
8. Bucasas K.L., Franco L.M., Shaw C.A., et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011, 203(7):921-929.
9. Nakaya H.I., Wrammert J., Lee E.K., et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12(8):786-795.
10. Li S., Rouphael N., Duraisingham S., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014, 15(2):195-204.
11. Obermoser G., Presnell S., Domico K., et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013, 38(4):831-844.
12. WHO Yellow fever. Fact sheet No100 March 2014 2014, WHO Media Centre.
13. Gaucher D., Therrien R., Kettaf N., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008, 205(13):3119-3131.
14. Querec T.D., Akondy R.S., Lee E.K., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10(1):116-125.
15. Karunamoorthi K. Malaria vaccine: a future hope to curtail the global malaria burden. Int J Prev Med 2014, 5(5):529-538.
16. Delva W., Abdool K.Q. The HIV epidemic in Southern Africa - is an AIDS-free generation possible?. Curr HIV/AIDS Rep 2014, 11(2):99-108.
17. Gengenbacher M., Kaufmann S.H. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012, 36(3):514-532.
18. Kaufmann S.H., McElrath M.J., Lewis D.J., Del G.G. Challenges and responses in human vaccine development. Curr Opin Immunol 2014, 28:18-26.
19. Archin N.M., Sung J.M., Garrido C., Soriano-Sarabia N., Margolis D.M. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol 2014, 12(11):750-764.
20. Ipp H., Zemlin A. The paradox of the immune response in HIV infection: when inflammation becomes harmful. Clin Chim Acta 2013, 416:96-99.
21. Stanisic D.I., Barry A.E., Good M.F. Escaping the immune system: How the malaria parasite makes vaccine development a challenge. Trends Parasitol 2013, 29(12):612-622.
22. Cambier C.J., Falkow S., Ramakrishnan L. Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell 2014, 159(7):1497-1509.
23. Richert L., Hue S., Hocini H., et al. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS 2013, 27(9):1421-1431.
24. Monaco A., Marincola F.M., Sabatino M., et al. Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett 2009, 583(18):3004-3008.
25. Vahey M.T., Wang Z., Kester K.E., et al. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine. J Infect Dis 2010, 201(4):580-589.
26. Zarate-Blades C.R., Silva C.L., Passos G.A. The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy. Clin Dev Immunol 2011, 2011:192630.
27. Maertzdorf J., Weiner J., Kaufmann S.H. Enabling biomarkers for tuberculosis control. Int J Tuberc Lung Dis 2012, 16(9):1140-1148.
28. Weiner J., Maertzdorf J., Kaufmann S.H. The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis. Ann N Y Acad Sci 2013, 1283:22-29.
29. Aranday C.E., Kaveh D., Nunez-Garcia J., Hogarth P.J., Vordermeier H.M. Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice. PLoS ONE 2010, 5(6):e11319.
30. Mollenkopf H.J., Hahnke K., Kaufmann S.H. Transcriptional responses in mouse lungs induced by vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis. Microbes Infect 2006, 8(1):136-144.
31. Bhuju S., Aranday-Cortes E., Villarreal-Ramos B., Xing Z., Singh M., Vordermeier H.M. Global gene transcriptome analysis in vaccinated cattle revealed a dominant role of IL-22 for protection against bovine tuberculosis. PLoS Pathog 2012, 8(12):e1003077.
32. Fletcher H.A., Keyser A., Bowmaker M., et al. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth. BMC Med Genomics 2009, 2:10.
33. Matsumiya M., Satti I., Chomka A., et al. Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model. J Infect Dis 2014, pii: jiu615.
34. Ritz N., Hanekom W.A., Robins-Browne R., Britton W.J., Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 2008, 32(5):821-841.
35. Ritz N., Dutta B., Donath S., et al. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. Am J Respir Crit Care Med 2012, 185(2):213-222.
36. Wu B., Huang C., Garcia L., et al. Unique gene expression profiles in infants vaccinated with different strains of Mycobacterium bovis bacille Calmette-Guerin. Infect Immun 2007, 75(7):3658-3664.
37. Carvalho C.L., Lopes dC.I., Ze-Ze L., Nuncio M.S., Duarte E.L. Tularaemia: a challenging zoonosis. Comp Immunol Microbiol Infect Dis 2014, 37(2):85-96.
38. Fuller C.L., Brittingham K.C., Porter M.W., et al. Transcriptome analysis of human immune responses following live vaccine strain (LVS) Francisella tularensis vaccination. Mol Immunol 2007, 44(12):3173-3184.
39. Garcia-Pineres A.J., Hildesheim A., Dodd L., et al. Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol 2009, 182(3):1706-1729.
40. Haralambieva I.H., Oberg A.L., Dhiman N., et al. High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination. J Infect Dis 2012, 206(10):1512-1520.
41. Haralambieva I.H., Ovsyannikova I.G., Pankratz V.S., Kennedy R.B., Jacobson R.M., Poland G.A. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines 2013, 12(1):57-70.
42. Lu Y., Cheng Y., Yan W., Nardini C. Exploring the molecular causes of hepatitis B virus vaccination response: an approach with epigenomic and transcriptomic data. BMC Med Genomics 2014, 7:12.
43. Kumar R., Engwerda C. Vaccines to prevent leishmaniasis. Clin Transl Immunol 2014, 3(3):e13.
44. Gannavaram S., Dey R., Avishek K., Selvapandiyan A., Salotra P., Nakhasi H.L. Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications. Front Immunol 2014, 5:241.
45. Maisonneuve C., Bertholet S., Philpott D.J., De G.E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A 2014, 111(34):12294-12299.
46. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 1996, 93(21):11341-11348.
47. Guerra S., Najera J.L., Gonzalez J.M., et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 2007, 81(16):8707-8721.
48. Appaiahgari M.B., Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther 2015, 15(3):337-351.
49. Opferman J.T., Ober B.T., Ashton-Rickardt P.G. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 1999, 283(5408):1745-1748.
50. Roychoudhuri R., Lefebvre F., Honda M., et al. Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. Vaccine 2015, 33(7):914-923.
51. Neeland M.R., Elhay M.J., Powell D.R., Rossello F.J., Meeusen E.N., de Veer M.J. Transcriptional profile in afferent lymph cells following vaccination with liposomes incorporating CpG. Immunology 2014, 144:518-529.
52. Schijns V.E., Strioga M., Ascarateil S. Oil-based emulsion vaccine adjuvants. Curr Protoc Immunol 2014, 106:2-7.
53. Mosca F., Tritto E., Muzzi A., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008, 105(30):10501-10506.
54. Kwissa M., Nakaya H.I., Oluoch H., Pulendran B. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 2012, 119(9):2044-2055.